학술논문
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
Document Type
Article
Author
Source
In Annals of Oncology August 2017 28(8):1817-1824
Subject
Language
ISSN
0923-7534